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INTRODUCTION
Central nervous system (CNS) involvement by non-
Hodgkin’s lymphoma (NHL) carries a poor patient progno-
sis [1-6]. CNS involvement occurs as a secondary site of
d i sease in 5% to 19% of patients with advanced systemic
NHL [2,3]. A review of 2 Southwest Oncology Gro u p
studies demonstrated a median survival of 2 months after the
diagnosis of secondary CNS disease [1]. A 1982 Stanford
University study showed comparably poor results, with a
median survival of only 9 weeks [7]. Mortality in these
patients is often the result of pro g ressive systemic NHL
rather than refractory CNS disease.
P r i m a ry CNS involvement occurs as a distinct clinical
entity that accounts for 1% to 2% of cases of NHL [5,8].
Despite the use of intensive therapies, including CNS radia-
tion [3-5], combination chemotherapy with or without
r a d i otherapy [8-12], and systemic chemotherapy with osmotic
d i s ruption of the blood-brain barr i e r, median survival re m a i n s
p o o r. In addition, these therapies have often resulted in
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ABSTRACT
Central nervous system (CNS) involvement by non-Hodgkin’s lymphoma (NHL) carries a poor patient pro g n o s i s
whether it occurs as a primary site of disease or secondarily in patients with systemic disease. In a group of
481 patients undergoing high-dose therapy with hematopoietic cell transplantation (HCT) for NHL, 15 patients
(3.1%) were identified with CNS involvement. Two patients had primary CNS lymphoma, and 13 had secondary
disease. All patients received intrathecal chemotherapy, and 13 received CNS radiotherapy before transplantation.
F o u rteen patients received systemic chemotherapy. At the time of transplantation, both patients with primary
CNS lymphoma and 8 patients with secondary disease had achieved a complete response, 3 patients had achieved
a partial response, 1 had failed induction therapy, and 1 had pro g ression of CNS disease before high-dose therapy.
F o u rteen patients received carmustine, etoposide, and cyclophosphamide as the preparative regimen, and 1
patient received fractionated total body irradiation instead of carmustine. The 2 patients with primary CNS lym-
phoma were alive and free of disease, 1 at 1085 days after HCT and 1 at 3704 days after HCT. The actuarial 5-
year event-free survival (EFS) was 46% ± 26%, and overall survival (OS) was 41% ± 28%. The median EFS and
OS were 2.2 and 1.5 years, re s p e c t i v e l y. Three patients experienced symptomatic memory loss or intellectual
decline after therapy, 1 patient developed paraplegia, and 1 patient had a thrombotic stroke 20 months after
H C T. Despite tre a t m e n t - related toxicities, 7 patients responding to quality-of-life questions at a p p roximately 1
year after HCT gave their overall quality of life a median rating of 9 out of a possible 10 (range, 6-10). High-
dose therapy with autologous HCT can produce extended EFS in patients with secondary CNS lymphoma and
possibly in those with primary CNS NHL. 
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s i g n i ficant late neuro t o x i c i t y. At this time the optimal man-
agement of patients with CNS disease remains unclear.
High-dose therapy with autologous hematopoietic cell
transplantation (HCT) is superior to standard-dose therapy and
can be curative for patients with recurrent intermediate- and
high-grade NHL [13]. There are sparse data concerning the
use of autologous HCT in patients with secondary CNS
lymphoma [14,15]. European Bone Marrow Tr a n s p l a n t
(EBMT) Lymphoma Registry data demonstrate that
patients with responsive NHL and CNS disease may
achieve durable remissions with HCT [14]. Not surpris-
ingly, patients with persisting CNS lymphoma at the time of
high-dose therapy respond poorly to HCT. To date, there
a re no published re p o rts of autologous HCT for patients
with primary CNS lymphoma (PCNSL).
To evaluate the role of high-dose therapy in patients
with CNS lymphoma, we reviewed the re c o rds of patients
who underwent autologous HCT for NHL at Stanford
University Medical Center. In this group of 481 patients
w e re 15 patients (3.1%) with CNS involvement by NHL,
including 2 patients with primary CNS lymphoma. This
report reviews the course and outcome of these patients.
PATIENTS AND METHODS
Pa t i e n t s
Between September 1988 and December 1998, 481 patients
with NHL underwent high-dose therapy with autologous
HCT at Stanford University Medical Center. A database
review identified 15 patients with CNS involvement by
NHL. Patient characteristics are detailed in the Table. All
t reatment protocols were reviewed and approved by the
Human Subjects Committee of the Stanford University
Medical Center.
High-Dose Therapy
The high-dose preparative regimen consisted of either
carmustine (15 mg/kg, to a maximum dose of 550 mg/m2) or
12 Gy of fractionated total body irradiation (fTBI), foll o w e d
by etoposide (60 mg/kg) and cyclophosphamide (100
mg/kg of ideal body weight). This regimen was adminis-
tered as previously described [16,17].
Patients who underwent transplantation after August
1993 received chemotherapy and granulocyte colony-
s t i m ulating factor (G-CSF)–mobilized and purged periph-
eral blood progenitor cells (PBPCs) rather than bone marrow
grafts [18]. Patients who underwent transplantation before
then received purged bone marrow grafts. Some of the bone
m a rrow and all of the PBPC grafts were purged with a panel
of monoclonal antibodies (mAbs) directed against either B-
cell (CD9, CD10, CD19, or CD20) or T-cell (CD2, CD3,
CD4, CD5, CD6, or CD8) antigens and rabbit complement
[16,19]. The methods for bone marrow and PBPC collection
have been previously described [18,19].
Posttransplantation supportive care included hospital-
ization in private, air-filtered rooms, antimicrobial therapy,
and blood product transfusion support as pre v i o u s l y
described [16]. Patients who were treated after April 1991
received G-CSF 5 µg/kg daily commencing on day 1 after
stem cell transplantation and continuing through the period
of neutrophil recovery [16,20]. 
Q u a l i t y - o f - L i f e Assessment
Commencing at day 90 and continuing through 1 year
after HCT, surviving patients were asked to respond to a
telephone survey reviewing selected quality-of-life parame-
ters. The 1-year time point was chosen for review to evalu-
ate patients’ overall quality of life after completion of post-
transplantation therapy and re c o v e ry from acute
treatment-related toxicities. The questionnaires were devel-
oped internally to address issues unique to the transplanta-
tion process but were modeled on other measures that
assessed overall health, employment, marital, sexual, and
functional status. Patients were asked to assign an overall
numeric score to their quality of life on a scale of 1 to 10
(with 1 being a “low point” in life, and 10 the “best ever”).
The questionnaires were administered by a nursing special-
ist and scored as previously described [21].
Statistical Anal y s i s
E v e n t - f ree survival (EFS) and overall survival (OS)
w e re determined from the time of transplantation to the
date of documented re c u rrence, death, or most recent fol-
low-up. OS and EFS curves were derived using the meth-
ods of Kaplan and Meier [22].
RESULTS
T h e r a py Bef o re Tr a n s p l a n t a t i o n
CNS involvement was documented by cytology in
7 patients (patient numbers [SPN] 50, 126, 135, 940, 999,
1405, and 1409), cytology and imaging studies in 2 patients
(SPN 1303 and 1502), biopsy in 3 patients (SPN 387, 842,
and 1515), and imaging studies alone in 3 patients (SPN
138, 295, and 1330). Two patients had primary CNS lym-
phoma (1 with leptomeningeal disease and 1 with cauda
equina disease, a positive cerebrospinal fluid cytology result,
and brain parenchymal abnormalities on a magnetic re s o-
nance imaging [MRI] scan). Thirteen patients had sec-
ondary CNS involvement. CNS disease was present in 5 of
these patients at the time of diagnosis and was diagnosed in
8 patients at the time of pro g ression during therapy or
relapse. Fourteen of 15 patients received doxorubicin-based
combination chemotherapy before PBPC mobilization. One
patient (SPN 50) with primary CNS lymphoma was treated
with intrathecal (IT) therapy and cranial-spinal radiotherapy
alone before high-dose therapy. All patients received IT
therapy with methotrexate, cytarabine, or both before trans-
plantation. Thirteen of 15 patients received CNS radiother-
apy before HCT (pretransplantation CNS radiotherapy is
detailed in the Table).
B e f o re HCT, both of the pat ients with PCNSL
achieved a complete response (CR). Of the 5 patients with
s e c o n d a ry CNS disease identified at the time of diagnosis,
2 (SPN 940 and 1405) achieved a CR before HCT, 3 (SPN
138, 295, and 1330) had residual imaging study abnormali-
ties in the CNS, and 1 (SPN 138) had residual bulky
adenopathy. Of the 8 patients who had CNS disease identi-
fied at relapse or pro g ression, 6 (SPN 126, 135, 387, 842,
999, and 1409) achieved a CR; 1 (SPN 1515) had a residual
MRI parenchymal abnorm a l i t y, and another (SPN 1502)
developed new MRI evidence of lumbar spine nerve ro o t
abnormalities after mobilization.
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High-Dose Therapy and T r a n s p l a n t a t i o n
F o u rteen patients received carmustine, etoposide, and
cyclophosphamide as their preparative regimen. One patient
who did not receive pretransplantation radiotherapy re c e i v e d
fTBI instead of carmustine. Hematopoietic cell support con-
sisted of bone marrow grafts in 6 patients, 3 of whom also
received a boost of peripheral blood mononuclear cells. Four
of the bone marrow grafts were purged with mAbs and c o m-
plement before cry o p re s e rvation; 1 was purged with 4-
h y d roxycyclophosphamide. All of the remaining patients
received chemotherapy (cyclophosphamide 4 gm/m2 [1 patient]
or etoposide 2 gm/m2 [8 patients]) and G-CSF–mobilized,
m A b - p u rged PBPC grafts.
The patients who received bone marrow grafts achieved
an absolute neutrophil count (ANC) ≥500/mm3 in a median
of 16.5 days (range, 9-19 days). Two patients did not achieve
platelet engraftment; 1 patient (SPN 135) experienced a
rapid bone marrow recurrence of NHL, and another (SPN
295) died of hepatic veno-occlusive disease before platelet
engraftment. The remaining 4 patients achieved a platelet
count ≥2 0 , 0 0 0 / m m3 in a median of 16 days (range, 15-21
days). Patients who received PBPC grafts achieved an ANC
≥500/mm3 and a platelet count ≥20,000/mm3 in a median of
8 days (range, 8-9 days) and 14 days (range, 11-23), respec-
tively. These recovery times are comparable to those previ-
ously published [16].
Posttransplantation Therapy
Six patients received posttransplantation therapy with
either radiotherapy or IT chemotherapy after adequate
hematologic re c o v e ry from high-dose therapy. Posttrans-
plantation therapy was perf o rmed at the discretion of the
investigator. None of the patients received both CNS radio-
therapy and IT chemotherapy after transplantation.
One patient (SPN 1405) received radiotherapy to the
paranasal sinuses after re c o v e ry from HCT. Five patients
received additional CNS therapy after transplantation.  Both
of the patients with PCNSL received additional IT chemo-
therapy (1 received 1 dose and 1 received 3 doses), 2 of the
patients with secondary CNS lymphoma received additional
IT therapy (1 received 5 doses and 1 received 11 doses), and 1
patient with secondary CNS lymphoma who had not under-
gone radiotherapy before transplantation received a radiation
dose of 35.3 Gy to the parasellar region of the brain.
Patient Characteristics, Therapy, and Outcome*
Pretrans-
Pretrans- Pretrans- plantation
Sites of plantation plantation Systemic CNS
SPN Age Sex Disease Histology Response Regimen Therapy Outcome
Primary CNS 50 40 M Meningeal DLCL CR None IT CCR (3704 d)
lymphoma 1303 42 M Parenchymal SNCCL CR CEPP, CHOP IT CCR (1085 d)
Secondary CNS 138 39 M Parenchymal DLCL IF MACOP-B R a d i o t h e r a p y CCR (3530 d)
lymphoma at 295 24 F Parenchymal DLCL, DM PR M-BACOD, CHOP None Hepatic veno-occlusive
diagnosis disease, death (21 d)
940 28 F Meningeal High-grade CR CHOP, high-dose None Relapse (33 d), 
( i m m u n o b l a s t i c ) methotrexate death (35 d)
1330 54 F Parenchymal DLCL PR CHOP IT CCR (800 d)
1405 24 M Meningeal DLCL CR CHOP R a d i o t h e r a p y CCR (761 d)
Secondary CNS 126 31 M Meningeal DM CR M-BACOD None Relapse (75 d), 
lymphoma at death (109 d)
r e l a p s e / p r o g r e s s i o n 135 53 M Meningeal DLCL, DM CR CHOP, MACOP-B, None Relapse (72 d),
COP-BLAM death (84 d)
387 51 F Parenchymal LL CR CHOP None CCR (2826 d)
842 33 F Parenchymal DLCL CR CAP, MACOP-B IT Relapse (579 d), 
death (1033 d)
999 47 M Meningeal FSCCL, DLCL CR CHOP, ESHAP, None Relapse (532 d), 
cytarabine death (799 d)
1409 24 M Meningeal LL CR Nebraska lymphoblastic None Relapse (76 d),
lymphoma regimen death (112 d)
1502 25 M Meningeal DLCL (T cell) PD CHOP, DHAP None Relapse (41 d), 
death (43 d)
1515 28 F Parenchymal DLCL PR CHOP None CCR (539 d)
*CAP indicates cyclophosphamide, doxorubicin, cisplatin; CCR, continuing complete response; CEPP indicates cyclophosphamide, etoposide,
procarbazine, prednisone; CHOP indicates cyclophosphamide, doxorubicin, vincristine, prednisone; COP-BLAM indicates cyclophosphamide,
vincristine, prednisone, bleomycin, doxorubicin, procarbazine; CR, complete response; DHAP indicates dexamethasone, cisplatin, cytarabine;
DLCL, diffuse large cell lymphoma; DM, diffuse mixed; ESHAP indicates etoposide, methylprednisolone, cisplatin, cytarabine; FSCCL, follicular
small cleaved cell lymphoma; IF, induction failure; LL, lymphoblastic lymphoma; MACOP-B indicates methotrexate, leucovorin, doxorubicin,
cyclophosphamide, vincristine, prednisone, bleomycin; M-BACOD indicates methotrexate, leucovorin, bleomycin, doxorubicin, cyclophos-
phamide, vincristine, dexamethasone; PD, progressive disease; PR, partial response; SNCCL, small, non-cleaved cell lymphoma (non-Burkitt’s);
SPN, patient number.
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O u t c o m e
Seven patients remained alive and free of disease after a
median follow-up of 1085 days after HCT (range, 539-
3704 days). The 2 patients with PCNSL were alive and dis-
ease free, 1 at 1085 days and 1 at 3704 days after transplanta-
tion. Five of 13 patients with secondary CNS involvement
w e re alive and well. For all 15 patients, the rate of OS and EFS
was 47% (7 of 15 patients). The 5-year actuarial OS was 41%
± 28% (95% confidence interval), and the 5-year actuarial
EFS was 46% ± 26% (95% confidence interv a l ) . The median
EFS and OS were 1.5 and 2.2 years, respectively (Figure ) .
One patient (SPN 1303) with primary CNS lymphoma and
spinal cord disease who was paraplegic at the time of HCT
gradually re c o v e red significant motor function within 6
months after HCT and is able to walk without assistance.
Seven patients experienced a recurrence of disease at a
median of 75 days (range, 33-582 days) after HCT. There
w e re no documented CNS relapses. Six patients died after
experiencing a relapse of NHL. One patient (SPN 295) died
of veno-occlusive disease of the liver on day 21 after trans-
plantation. No unusual  tre a t m e n t - related toxicities
o c c u rred. One patient (SPN 842) who experienced re l a p s e
died from secondary acute myelogenous leukemia (AML)
1033 days after transplantation. The patient with pro g re s-
sive CNS disease before the time of transplantation (SPN
1502) died from recurrent lymphoma.
CNS To x i c i t y
N e u ropsychiatric testing was not perf o rmed pro s p e c t i v e l y.
One patient (SPN 50) with primary CNS lymphoma experi-
enced a decline in neurocognitive function that led to discon-
tinuation of posttransplantation IT therapy. This patient was
unable to remain employed as a trial lawyer because of these
d e ficits. One patient (SPN 1303) re p o rted short - t e rm memory
loss, and another patient (SPN 1515) developed short- and
l o n g - t e rm memory deficits. Two patients with secondary CNS
disease had computed tomography (SPN 387) or MRI (SPN
842) evidence of therapy-related white matter changes. One
patient (SPN 1405) developed paraplegia, thought to be
caused by radiation-induced transverse myelitis, 2 years after
H C T. Another patient (SPN 1330) experienced a right-sided
t h rombotic stroke, believed to be unrelated to transplantation,
a p p roximately 20 months after high-dose therapy.
Q u a l i t y - o f - L i f e Assessment
Patients surviving transplantation underwent periodic
telephone surveys assessing their quality of life. At approxi-
mately 1 year after transplantation (range, 94 to 411 days),
7 of 9 surviving patients responded to the surv e y. Five of
7 patients were employed either full or part time. Tw o
patients re p o rted difficulties with sleep. One patient described
his or her appearance as “poor,” whereas 6 described it as
either “good” or “better than expected.” One patient (SPN
50) noted persisting fatigue, multiple gastrointestinal com-
plaints, and difficulties with gait. Another patient (SPN
1303) complained of impairment in memory. The remaining
patients assessed their overall level of energy as 80% to 90%
of their premorbid level. The responding group of patients
gave their overall quality of life a median rating of 9 out of a
possible 10 (range, 6-10).




The treatment of patients with CNS involvement by
NHL is difficult. Patients with secondary CNS disease
usually have been treated with a variety of re g i m e n s ,
i n c l u ding systemic high-dose methotrexate with leucov-
orin rescue [23], systemic high-dose cytarabine [24-26],
r a d i o t h e r a p y, and IT chemotherapy [7]. Despite cytologic
and imaging studies indicating clearing of the CNS,
pat ients often die  from pro g ressive systemic disease
[27,28]. Among 16 patients with the concomitant diag-
noses of systemic NHL and CNS NHL, median surv i v a l
was only 22 weeks, and only 3 patients survived for 1 year
[7]. Patients diagnosed with CNS disease at the time of
re c u rrence or pro g ression have a comparably dismal pro g-
nosis, with a median survival of only 2 months in one series
[27]. In multiple published series, the overall median sur-
vival for patients with secondary CNS involvement tre a t e d
with conventional-dose therapy ranged from only 9 weeks
to 10 months [1,2,7,29,30].
High-dose chemotherapy with autologous HCT may
p roduce long-term complete remissions in patients with
relapsed primarily re f r a c t o ry or high-risk NHL [13,16,
31,32]. EBMT Lymphoma Registry data support a possible
role for this treatment modality for patients with CNS
involvement by NHL. The EBMT Lymphoma Registry
study re t rospectively identified 62 patients with secondary
CNS NHL who underwent HCT at participating European
centers using a variety of total body irradiation (TBI)- and
non-TBI–based preparative regimens. The 5-year a c t u a r i a l
p ro g re s s i o n - f ree survival (PFS) was 42% for the 45 patients
who demonstrated CNS clearing before HCT and 9% for
the 17 patients with residual or re f r a c t o ry CNS disease.
Patients who received both radiotherapy and IT chemo-
therapy before HCT had a better outcome than those who
received either modality alone. Age, tumor histology, graft
p u rging, and the preparative regimen did not appear to
significantly alter patient outcome [14].
An M.D. Anderson Cancer Center (MDCC) study
re p o rted on 24 patients with CNS leukemia or NHL who
u n d e rwent either autologous or allogeneic HCT. Nine
patients in this series had secondary CNS NHL. Five of the
20 patients who demonstrated clearing of CNS leukemia or
lymphoma before transplantation were alive at the time of
the re p o rt; 4 were disease fre e . None of the 4 patients
(including 1 patient with NHL) who had active CNS dis-
ease at the time of HCT survived [15]. The variability in
patient diagnosis and type of transplantation, however,
makes it difficult to derive any clear conclusions re g a rd i n g
the use of autologous HCT for patients with secondary
CNS lymphoma.
The patient group re p o rted here includes 13 patients
with secondary CNS NHL. Unlike patients in the EBMT
Lymphoma Registry, these patients were treated using a
consistent preparative regimen at a single institution. All of
the patients were treated with the intention of clearing the
CNS before HCT. Five patients (38%) are alive and free of
disease after HCT. There have been no documented CNS
recurrences. Similar to the group with the best outcome in
the EBMT Lymphoma Registry report [14], all of the sur-
viving patients in this study received IT therapy and CNS
radiotherapy as part of their treatment regimen.
This re p o rt also includes what we believe to be the fir s t
re p o rt of the treatment of primary CNS lymphoma with
high-dose therapy and autologous HCT. PCNSL is a distinct
clinical entity in which there is involvement of the brain, lep-
tomeninges, or spinal cord with or without ocular disease,
and the absence of other systemic disease [4,8]. In addition,
local pro g ression, rather than systemic dissemination,
accounts for the majority of treatment failures [3-5]. Surg i c a l
re s e ction provides no improvement in survival, and CNS
r a d i o t h e rapy alone produces a median survival of only 12 to
16 months [4,6]. Combinations of radiotherapy with systemic
high-dose methotrexate have improved the response rate and
median survival [12]. Recently the Memorial Sloan-K e t t e r-
ing Cancer Center group has published a protocol that utilizes
systemic and intraventricular doses of methotrexate, high-dose
cytarabine, and CNS radiotherapy. This regimen pro d u c e d
complete responses in 27 of 31 patients and a median surv i v a l
of 41 months [8]. This approach, however, has been associated
with significant late neuro t o x i c i t y. 
The Oregon Health Sciences University group has used
osmotic disruption of the blood-brain barrier before sys-
temic chemotherapy with methotrexate, cyclophosphamide,
p rocarbazine, and dexamethasone [33]. This regimen pro-
duced complete responses in 29 of 34 evaluable patients not
previously treated with radiotherapy, with a median survival
of 41 months and no evidence of significant late neurotoxic-
ity on prospective neuropsychiatric tests [33]. Osmotic dis-
ruption, however, remains a cumbersome process, and
administration of this regimen may be complicated by
seizures, strokes, and sepsis.
One of the 2 patients with primary CNS lymphoma in
this re p o rt had brain parenchymal abnormalities and lep-
tomeningeal and cauda equina disease, whereas the other had
leptomeningeal disease alone. Both of these patients re m a i n
in remission at 1085 and 3704 days after transplantation,
re s p e c t i v e l y. Although the findings from our treatment gro u p
raise the prospect that high-dose therapy with HCT may
hold promise for some patients with primary CNS lym-
phoma, we cannot draw any definite conclusions re g a rd i n g
the potential efficacy of HCT in this patient population. Of
note, these 2 patients were younger than those included in
many PCNSL series, and age is an important determinant of
p rognosis in patients with this disease [9,34]. HCT, however,
may provide a mechanism for the use of intensified systemic
therapy and may avoid some of the significant complications
of dose-escalated therapy without stem cell support .
Late neuro t o x i c i t y, however, remains a concern for
patients receiving intensive CNS therapy [11,35]. Intellec-
tual impairment, seizures, dementia, and spinal cord
myelopathy have been re p o rted in survivors of childhood
acute lymphoblastic leukemia and CNS lymphoma [ 1 0 ,
11,35-37]. The MDCC report documented grade III or I V
t re a t m e n t - related neurotoxicity in 8 of 20 patients w h o s e
CNS was cleared of disease before HCT. Of the 15
patients in this group, 3 developed symptomatic neurot o x i c-
i t y, including impaired cognition/memory deficits in 3
patients and spinal cord myelopathy resulting in parapleg i a
in 1 patient. Two other asymptomatic patients had evidence
of leuko-encephalopathic changes on imaging studies. The
limited size of our treatment group and the lack of prospec-
tive neuropsychiatric testing preclude an exact characteriza-
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tion of any subclinical neurologic changes or a comparison
between the neurotoxicity of this regimen and that of other
therapeutic regimens.
Despite the potential for late neurologic toxicity associ-
ated with this treatment regimen, patients who responded to
the 1-year quality-of-life survey appeared overall to have a
positive assessment. Although the small number of surviving
patients limits the power of this tool to assess a global out-
come for this patient population, it is encouraging that the
majority of responding patients had resumed employment
and reported a good to excellent self-assessment. 
The three chemotherapeutic drugs used in this pre p a r a-
tive regimen all have the capacity to achieve some degree of
CNS penetration. Carmustine is a highly lipid-soluble dru g
that readily penetrates the CNS and achieves cere b ro s p i n a l
fluid concentrations that are greater than 50% of those in
plasma. Although the CNS penetration of etoposide and
cyclophosphamide is more limited, there may be factors that
enhance the penetration of these drugs in patients with CNS
disease [38-42]. Within brain parenchymal tumors, etoposide
may achieve concentrations that are 3.5% to 74.6% of those
in serum as a result of local disruption of the blood-brain
b a rr i e r. Similarly, cyclophosphamide may poorly penetrate
an intact blood-brain barrier but achieve higher concentra-
tions within intracerebral tumors [41,43]. A number of alter-
native chemotherapeutic agents, including nitrogen mustard ,
m e t h o t rexate, thiotepa, cytarabine, melphalan, and lomus-
tine, have good CNS penetration and could conceivably be
used in the development of novel high-dose treatment pro t o-
cols [4,42]. In protocols recently developed for the tre a t m e n t
of patients with primary CNS lymphoma, investigators are
attempting to use agents such as these without radiotherapy
in the hope of reducing the risk of late neurotoxicity [44].
This study demonstrates that high-dose therapy and
autologous HCT can produce extended disease-free sur-
vival in patients with secondary CNS involvement by
NHL. Available data indicate that if HCT is to be success-
ful, it is essential that clinicians attempt to clear the CNS
of disease before transplantation. This re p o rt also raises
the question of whether high-dose therapy with autologous
HCT may have the potential to play a role in the manage-
ment of patients with primary CNS lymphoma. Despite
the ability of high-dose therapy to produce durable re m i s-
sions in affected patients, this re p o rt illustrates that this
t reatment approach may be accompanied by a significant
d e g ree of neuro t o x i c i t y. Further study must be dire c t e d
t o w a rd the development of alternative high-dose pre p a r a-
tive regimens that limit or omit radiotherapy in the hope
of decreasing late neuro t o x i c i t y.
Authors’ Note: As this paper was going to press, one of
the patients (SPN 50) developed a right cerebellar mass that
was a biopsy-proven re c u rrence of non-Hodgkin’s lym-
phoma at 4000 days posttransplantation. At the time of last
follow-up, the patient was alive after 4 cycles of high-dose
methotrexate.
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